Compare Abeona Therapeutics Inc (ABEO) vs Hormel Foods Corp (HRL) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Abeona Therapeutics Inc vs Hormel Foods Corp — how do they compare? Abeona Therapeutics Inc trades at $6.72 (market cap $373.32M), while Hormel Foods Corp trades at $24.53 (market cap $13.59B). The key difference: Hormel Foods Corp is far larger — about 36.4× Abeona Therapeutics Inc's market cap, and Hormel Foods Corp pays a 4.74% dividend while Abeona Therapeutics Inc pays none. Which is the better fit depends on your goals.
| ABEO | HRL | |
|---|---|---|
Market Cap | $373.32M | $13.59B |
Sector | Health | Consumer Staples |
52-Week High | $7.23 | $31.54 |
52-Week Low | $4.17 | $19.74 |
Enterprise Value | $228.22M | $15.59B |
Dividend Yield | — | 4.74% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ABEO trades at $6.31, down 1.41% today, with a bullish technical outlook supported by moving averages. The company reported Q1 2026 results with revenue growth and beat EPS expectations, while maintaining strong profitability margins. Recent news highlights expansion of treatment centers and new cell therapy licensing.
Outlook remains positive with analyst consensus favoring Buy ratings (66.67%), though high RSI indicates potential near-term overbought conditions. Key risks include negative operating cash flow and reliance on new treatment adoption. Upside depends on continued commercial execution and pipeline advancements.
Hormel Foods (HRL) trades at $24.70, down 1.2% on the day, with a mixed technical outlook showing bullish overall signals but bearish moving averages. The stock has consistently beaten earnings estimates in recent quarters, though net income margin has compressed to 3.82%. Recent corporate actions include steady $0.29 dividends, while the company sold its Brazilian Ceratti operations to sharpen international focus. Analyst consensus price target is $25.00, slightly above current levels.
HRL offers a stable dividend profile as a Dividend King but faces margin pressure and modest growth. Near-term upside appears limited given current valuation and mixed analyst ratings. Key risks include input cost inflation and competitive pressures in the consumer staples sector. The stock presents a defensive income opportunity rather than significant capital appreciation potential in the current environment.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Abeona Therapeutics Inc
Abeona Therapeutics develops gene and cell therapies for rare diseases. Its lead product, ZEVASKYN, is an FDA-approved therapy for recessive dystrophic epidermolysis bullosa (RDEB), a severe and life-threatening genetic skin disorder.
Read more on ABEO →About Hormel Foods Corp
Hormel Foods is a protein-focused branded food company. Its brands include its namesake Hormel, Spam, Jennie-O, Dinty Moore, Applegate, Wholly Guacamole, and Skippy. The vast majority of the company's revenue is U.S.-based: 64% U.S. retail, 28% U.S. food service, and 8% international. By product type, in fiscal 2021, 23% of revenue was shelf-stable foods, 18% was poultry (branded and commodity), 55% was other perishable food, and 3% was other, primarily nutritional products. The company holds the number-one market position in shelf-stable meat, shelf-stable ready meals, pepperoni, natural/organic deli meat, and guacamole and the number-two position in turkey, bacon, chilled ready meals, and peanut butter.
Read more on HRL →
